Want to see KYNB full AI Analyst Report?
Revenue by Segment
Breaks revenue into streams such as product sales, licensing, collaboration income, services, and grants so you can see what actually pays the bills. Highlights whether cash flow is driven by repeatable sales or by one‑time milestone and partnership payments, which affects predictability and near‑term funding needs.FibroGen's revenue from the Product segment surged in 2024 but dropped to zero by year-end, indicating a strategic pivot or product discontinuation. The earnings call reveals a focus on simplifying operations through the sale of FibroGen China, extending the cash runway into 2028. Despite limited revenue growth and ongoing net losses, the company is advancing clinical trials for FG-3246 and roxadustat, signaling a shift towards innovation in oncology and anemia treatments. This strategic realignment could drive future growth, albeit with near-term financial challenges.
Date | Product | License | Developement & Other | Drug Product |
|---|---|---|---|---|
Jun 30, 2025 | $0.00 | $0.00 | $133.00K | $1.22M |
Mar 31, 2025 | $0.00 | $0.00 | $144.00K | $2.60M |
Dec 31, 2024 | $0.00 | $0.00 | $416.00K | $2.72M |
Sep 30, 2024 | $46.21M | $0.00 | $385.00K | -$262.00K |
Jun 30, 2024 | $49.64M | $0.00 | $269.00K | $729.00K |
Mar 31, 2024 | $30.54M | $0.00 | $878.00K | $24.49M |
Dec 31, 2023 | $23.51M | $0.00 | $2.58M | $1.05M |
Sep 30, 2023 | $29.39M | $2.65M | $6.78M | $1.32M |
Jun 30, 2023 | $23.89M | $1.00M | $5.16M | $14.27M |
Mar 31, 2023 | $24.16M | $6.00M | $3.89M | $2.11M |